scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Aug 7, 2025
Generated net FUROSCIX® revenue of $16 million in the second quarter of 2025; up 99% over Q2 2024
Doses shipped to patients increased 45% over Q1 2025 and 117% over Q2 2024
Read more at globenewswire.com
